Discovery of Viagra’s Role in Curbing Cancer Spread
Researchers in Israel have made an unexpected finding: Viagra, typically known for treating erectile dysfunction in men, may also play a role in slowing cancer progression. Scientists at the Weizmann Institute of Science have identified how sildenafil, Viagra’s active compound, disrupts the cholesterol supply in cancer cells. This cholesterol is essential for their ability to spread to other organs.
Dr. Yarden Ariav led the study under the guidance of Prof. Ayelet Erez at Weizmann, collaborating with experts from the US National Cancer Institute, Clalit Health Services in Israel, and Rabin Medical Center.
The research, published in July in Cancer Research, utilized various methods, including mouse cancer models and cancer cell cultures from humans, alongside data compiled from around 5 million Clalit members collected over two decades.
The data indicated that patients who used both sildenafil and statins—a common group of cholesterol-lowering medications—six months ahead of their cancer diagnosis had better survival rates.
The lab work primarily focused on types of cancer like triple-negative breast cancer, melanoma, and lung cancer. Dr. Erez mentioned that patient data corroborated their mouse study findings for lung, colon, and prostate cancer.
Looking ahead, Erez expressed the desire to expand the research to include women, particularly those with triple-negative breast cancer, potentially using a drug that’s conventionally linked to male health.
Understanding the Mechanism
Sildenafil was originally developed to treat heart conditions by dilating blood vessels. Its effectiveness in treating erectile dysfunction was recognized in 1998. The research team administered the drug to both male and female mouse models and human cancer cells. They employed high-resolution cellular imaging techniques to observe the drug’s immediate effects, which included the inhibition of phosphodiesterase type 5 (PDE5). This led to an increase in cyclic GMP (cGMP), a crucial messenger molecule.
This process caused cGMP to trap a protein that transports cholesterol, which cancer cells need to metastasize. Without this cholesterol, the cancer cells were hindered in their ability to spread, resulting in fewer metastatic occurrences.
Dr. Erez stated that their findings reveal a new biological pathway that could potentially be leveraged for treatment.
Interestingly, the cancer cells didn’t simply stop there. When sildenafil removed accessible cholesterol, the cells figured out how to produce more on their own. At this point, the researchers introduced statins alongside sildenafil.
Dr. Samah Hayek, a senior epidemiologist at Clalit Health Services, discussed how researchers wanted to align their lab findings with real-world patient data. They focused on cancer patients who had taken both Viagra and statins before their diagnosis.
Using various statistical approaches, Hayek confirmed that the lab findings were consistent with the outcomes seen in patient data. This intersecting of lab and real-world data has led to informative conclusions.
Dr. Ido Wolf, head of oncology at Tel Aviv Medical Center, commented on the significance of the study, noting the previously overlooked connection between cholesterol and cancer cell behavior. He emphasized the potential for rapidly repurposing established medications like sildenafil and statins.
Erez also pointed out the importance of not just isolating cancer mutations or the tumor environment, but also considering patient lifestyle factors, including diet and exercise, alongside medication use.






